Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
157 Results for "
antigen presentation
" in MedChemExpress (MCE) Product Catalog:
Products (157)
157 Results for "antigen presentation" in MCE Product Catalog:
4
Target:
PROTACs FKBP Epigenetic Reader Domain HDAC Histone Methyltransferase c-Myc Polo-like Kinase (PLK) Ras MHC
Research Areas:
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12 F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12 F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12 F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRAS G12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research .
2
2 Cited Publications
Target:
Research Areas:
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression .
1
1 Cited Publications
Cat. No.: HY-161541
1
1 Cited Publications
Cat. No.: HY-P5623
CAS No.: 115136-25-9
Synonyms: RVG29; RDP; Rabies Virus Glycoprotein-29
Target:
Research Areas:
1
1
Target:
Research Areas:
1
1 Cited Publications
ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma .
1
1 Cited Publications
Synonyms: ODN 2006; PF-3512676; CpG 7909; ODN 7909
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
Cat. No.: HY-161543
Cat. No.: HY-176778
CAS No.: 2790420-60-7
Target:
Research Areas:
BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC50 of 19 nM. BDM88951 significantly inhibits antigen presentation. BDM88951 can be used for autoimmune diseases and cancers research .
Cat. No.: HY-161553
Cat. No.: HY-161533
Cat. No.: HY-161560
Cat. No.: HY-145976
CAS No.: 133608-76-1
Research Areas:
m7GpppGpG is an unmodified trinucleotide cap analog with enhancer activity. When incorporated into mRNA, it effectively enhances translational efficiency, stability, and protein expression levels of the mRNA. m7GpppGpG can serve as a standard cap analog for in vitro mRNA synthesis to support antigen generation and presentation by dendritic cells, although its expression efficiency in dendritic cells is 20-fold lower than that of the m7GpppApG cap .
Cat. No.: HY-161552
Cat. No.: HY-161526
Cat. No.: HY-117573
CAS No.: 1438280-73-9
Target:
Research Areas:
1Z105 is an oral active TLR4/MD2 ligand. 1Z105 enhances dendritic cell maturation and antigen presentation and prevents rthritis .
Cat. No.: HY-161566
Cat. No.: HY-158279
Cat. No.: HY-157171
CAS No.: 126530-17-4
Target:
Research Areas:
Ac-YR-NH2 is a small molecule modulator of MHC class II antigen presentation. Ac-YR-NH2 can influence peptide binding by MHC II to influence immune response .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
